Generics in Spain

Date: January 4, 2016
Pages: 32
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GC774D7D726EN
Leaflet:

Download PDF Leaflet

Generics in Spain
INTRODUCTION

Generics in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Spain generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Spanish generics market is expected to generate total revenues of $3.5bn in 2015, representing a compound annual growth rate (CAGR) of 6.2% between 2011 and 2015.
  • Market consumption volume is forecast to reach a total of 81.6% of total pharma volume in 2015.
  • In Spain there is a great deal of difference in per capita public pharmaceutical expenditure. There is also a big difference in terms of prescriptions per capita. This is largely caused by differences in the age of its population in different areas. However, this gap is slowly closing. In 2014, the variation coefficient passed to 12.7% from 13.2% in 2013.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Spain
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Spain
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Spain generics market with five year forecasts by both value and volume
  • Macroeconomic indicators provide insight into general trends within the Spain economy
KEY QUESTIONS ANSWERED
  • What was the size of the Spain generics market by value in 2015?
  • What will be the size of the Spain generics market in 2020?
  • What factors are affecting the strength of competition in the Spain generics market?
  • How has the market performed over the last five years?
  • How large is Spain’s generics market in relation to its regional counterparts?
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Esteve Group
Mylan Inc.
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country Data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: Spain generics market value: $ billion, 2011–15(e)
Table 2: Spain generics market volume: % of total pharma volume, 2011–15(e)
Table 3: Spain generics market geography segmentation: $ billion, 2015(e)
Table 4: Spain generics market value forecast: $ billion, 2015–20
Table 5: Spain generics market volume forecast: % of total pharma volume, 2015–20
Table 6: Esteve Group: key facts
Table 7: Mylan Inc.: key facts
Table 8: Mylan Inc.: key financials ($)
Table 9: Mylan Inc.: key financial ratios
Table 10: Sandoz International GmbH: key facts
Table 11: Teva Pharmaceutical Industries Limited: key facts
Table 12: Teva Pharmaceutical Industries Limited: key financials ($)
Table 13: Teva Pharmaceutical Industries Limited: key financial ratios
Table 14: Spain size of population (million), 2011–15
Table 15: Spain gdp (constant 2005 prices, $ billion), 2011–15
Table 16: Spain gdp (current prices, $ billion), 2011–15
Table 17: Spain inflation, 2011–15
Table 18: Spain consumer price index (absolute), 2011–15
Table 19: Spain exchange rate, 2011–15

LIST OF FIGURES

Figure 1: Spain generics market value: $ billion, 2011–15(e)
Figure 2: Spain generics market volume: % of total pharma volume, 2011–15(e)
Figure 3: Spain generics market geography segmentation: % share, by value, 2015(e)
Figure 4: Spain generics market value forecast: $ billion, 2015–20
Figure 5: Spain generics market volume forecast: % of total pharma volume, 2015–20
Figure 6: Forces driving competition in the generics market in Spain, 2015
Figure 7: Drivers of buyer power in the generics market in Spain, 2015
Figure 8: Drivers of supplier power in the generics market in Spain, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Spain, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in Spain, 2015
Figure 11: Drivers of degree of rivalry in the generics market in Spain, 2015
Figure 12: Mylan Inc.: revenues & profitability
Figure 13: Mylan Inc.: assets & liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets & liabilities
Skip to top


Emerging Generic Drug Markets in Europe US$ 1,390.00 Dec, 2007 · 196 pages

Ask Your Question

Generics in Spain
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: